Fate Therapeutics, Inc. (FATE)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.9M | 1.7M | 1.4M | 1.3M |
| Operating Income | -37.0M | -34.7M | -34.7M | -33.0M |
| Net Income | -34.1M | -32.2M | -32.4M | -31.2M |
| Diluted EPS | $-0.29 | $-0.27 | $-0.27 | $-0.26 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 96.3M | 63.5M | 13.6M | 6.6M |
| Operating Income | -308.4M | -190.5M | -195.5M | -147.7M |
| Net Income | -281.7M | -160.9M | -186.3M | -136.3M |
| Diluted EPS | $-2.91 | $-1.64 | $-1.64 | $-1.15 |